MedPath

ZETA : Prospective Observational Study

Completed
Conditions
Metastatic Colon Cancer
Registration Number
NCT03730558
Lead Sponsor
Recherche clinique
Brief Summary

Primary objective

- Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with oxaliplatin + EGFR.

Secondary objective

* Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall survival rate and the objective response rate.

* Evaluate the tolerance profile of aflibercept in combination with FOLFIRI.

* Observational study, national, multicenter, cohort, prospective without intervention on the therapeutic strategy.•

Detailed Description

Inclusion criteria

* All patients expected to be treated with aflibercept in combination with FOLFIRI for a mCRC, after failure of treatment with oxaliplatin + anti-EGFR on the decision of the doctor (situation included in the framework of the MA of aflibercept) .

* Age ≥18 years

* Signature of the agreement for the collection of medical and personal data. (Patients who have received FOLFIRINOX in the first line metastatic are allowed) Note: Failure is defined as progression during or within 6 months after discontinuation of oxaliplatin

Exclusion criteria :

* Concurrent participation in a clinical trial

* Patients who have previously received anti-VEGF agents and / or aflibercept in one trial.

* Patients who received FOLFIRI in the first metastatic line.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment2 years

progression-free survival (PFS)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Institut Sainte-Catherine

🇫🇷

Avignon, Vaucluse, France

Institut Sainte Catherine

🇫🇷

Avignon, France

© Copyright 2025. All Rights Reserved by MedPath